Inhibikase Therapeutics, Inc.
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$48.3M
- Total assets
- $181.2M
- Market cap
- $215.2M
- Operating margin
- -1399.0%
- Net margin
- -1299.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.7M
- Operating expenses
- $55.7M
- Operating income
- -$52.0M
- Income tax
- $0
- Net income
- -$48.3M
- EPS (basic)
- $-0.49
- EPS (diluted)
- $-0.49
Balance sheet
- Total assets
- $181.2M
- Current assets
- $180.1M
- Total liabilities
- $8.3M
- Current liabilities
- $8.3M
- Shareholders’ equity
- $172.9M
Cash flow
- Operating cash flow
- -$27.8M
- Investing cash flow
- $2.1M
- Financing cash flow
- $108.5M
- Net cash flow
- $82.7M
Statements via Polygon.io (SEC filings)
- Market cap
- $215.2M
- EPS (diluted)
- $-0.49
- Shares outstanding
- 132.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 23, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $48.3M in FY2024.
- Revenue grew 20% from FY2021 to FY2025.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inhibikase Therapeutics, Inc..
Write a review
News about Inhibikase Therapeutics, Inc.
News & sentiment via Polygon.io
